Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU- Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?

DOI: 10.1007/s40259-019-00357-2
BioDrugs, 2019, 33, 437-446.

#	Paper	IF	Citations
9	Comment on "Analysis of Pharmacokinetic and Pharmacodynamic Parameters in EU-Versus US-Licensed Reference Biological Products: Are In Vivo Bridging Studies Justified for Biosimilar Development?". *BioDrugs*, **2019**, 33, 581-582	7.9	1
8	Physicochemical analysis and biological characterization of FKB327 as a biosimilar to adalimumab. *Pharmacology Research and Perspectives*, **2020**, 8, e00604	3.1	6
7	Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars. *BioDrugs*, **2020**, 34, 225-233	7.9	4
6	Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance. *BioDrugs*, **2021**, 35, 379-387	7.9	1
5	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. *Drugs*, **2021**, 81, 1859-1879	11.1	3
4	Pharmacokinetics of Biologics. **2020**, 125-145		1
3	Innovative Design and Analysis for PK/PD Biosimilar Bridging Studies with Multiple References. *AAPS Journal*, **2021**, 24, 3	3.7	
2	Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. *BioDrugs*,	7.9	0
1	Biosimilars: Harmonizing the Approval Guidelines. **2022**, 2, 171-195		0